Montelukast Stada

Montelukast, the active ingredient in Montelukast Stada, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as part of maintenance therapy. It is indicated for long‑term control of symptoms and reduction of exacerbations, and may be prescribed for patients with intermittent or persistent disease patterns.

GNH USA supplies Montelukast Stada as a licensed, GDP‑compliant international pharmaceutical supplier, providing regulated, quality‑assured batches to hospitals, pharmacies, and clinics worldwide, with support for import documentation and logistics across multiple markets.

Montelukast is a leukotriene receptor antagonist used in the management of respiratory and allergic conditions.

Asthma: Provides maintenance therapy that improves symptom control, decreases nighttime awakenings, and significantly reduces the need for rescue inhalers in patients with persistent asthma. Allergic rhinitis: Alleviates nasal congestion, rhinorrhea, sneezing and itchy eyes in seasonal or perennial allergic rhinitis, supporting better daily functioning. Exercise‑induced bronchoconstriction: Prevents airway narrowing that occurs during or after vigorous physical activity, allowing patients to exercise with fewer respiratory symptoms.

Montelukast is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate head pain. - Upper respiratory tract infection: symptoms of cold or flu. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools. - Cough: occasional dry cough. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Allergic reactions (angioedema, anaphylaxis): swelling of face, throat or severe hypersensitivity. - Mood changes (depression, suicidal thoughts): new or worsening mental health symptoms. - Hepatotoxicity (elevated liver enzymes): signs of liver injury. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering. - Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis): systemic vasculitis with eosinophilia.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess asthma control: confirm patient is on appropriate inhaled therapy before adding Montelukast. - Monitor for neuropsychiatric events: watch for depression, agitation or suicidal ideation. - Evaluate liver function: consider baseline tests in patients with hepatic disease. - Use in pediatric patients: follow age‑specific safety data and dosing recommendations. - Avoid in patients with known hypersensitivity to Montelukast or any tablet excipients. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Montelukast may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital, carbamazepine, phenytoin: enzyme inducers that can reduce Montelukast plasma levels. - Ritonavir: strong CYP3A4 inhibitor that may increase Montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Fluconazole: moderate CYP3A4 inhibition may raise Montelukast levels. - Antidepressants (e.g., fluoxetine): possible additive neuropsychiatric effects. - Theophylline: may increase risk of side effects; monitor levels.